Asset profile
CAN04
Monoclonal antibody
Evidence outlook · lead readout
NCT03267316 · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT03267316: The study was nonrandomized, open-label, and had no standalone comparator arm, although it enrolled 167 participants across dose-escalation, monotherapy, and combination cohorts. Results for the primary safety endpoint were not posted, so the study provides limited controlled evidence of CAN04’s effects.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.